There are currently 1498 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 2, Dallas, Texas +1 locations
Conditions: FSGS
Register for Updates
Brain Metabolism Observed at 7 Tesla
NCT05085704
Recruiting
The goal is to develop methodology to monitor flux in the citric acid cycle in brain via 13C nuclear magnetic resonance (NMR) spectroscopy at 7 Tesla.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
10/23/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Glut1 Deficiency Syndrome 1, Glucose Metabolism Disorders, Epilepsy, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Transporter Type 1 Deficiency Syndrome, Glucose Transporter Protein Type 1 Deficiency Syndrome, Glucose Transport Defect
Register for Updates
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy
NCT05995236
Recruiting
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
Rib Fracture Cryoanalgesia
NCT06093776
Recruiting
Rib fractures lead to poor patient outcomes and even death 3. Data suggests effective pain management is crucial to obtain favorable outcomes 4, 5Current outpatient treatment modalities are limited to oral or topical medications with low efficacy and high risk for opioid dependence. In-patient management with a thoracic epidural TEA is largely considered the gold standard, but the risks of TEA may outweigh the benefits 6 to 8.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/17/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Pain Management Improvement
Register for Updates
Don't Treat Ghosts Anti-MRSA Antibiotics in Osteomyelitis Without Identified MRSA
NCT06096012
Recruiting
Osteomyelitis is described as infection and inflammation of the long bone or bone marrow, often due to an open wound, operation, or invasive trauma.1 It is invasive and involves hematogenous seeding or contiguous spread of the infectious organism
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/17/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Osteomyelitis
Register for Updates
Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage
NCT06096051
Recruiting
Intracranial hemorrhage (ICH) can occur due to traumatic and spontaneous events.1 The incidence of non-traumatic, spontaneous ICH is approximately 40,000 to 67,000 cases per year while the incidence of traumatic brain injury (TBI) is nearly 1.7 million annually
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/17/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Intracranial Hemorrhage
Register for Updates
Extracellular RNA Biomarkers of Myotonic Dystrophy
NCT05020002
Recruiting
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
10/04/2023
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Myotonic Dystrophy
Register for Updates
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
NCT02577302
Recruiting
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system. Subjects from both groups will immediately start with therapy. The primary endpoint is a ≥ 50% reduction in number of incontinence episodes associated with urgency at the 3-month visit, with additional measurements assessed at 14 days, 1, 6, 9 and 12-months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Urinary Incontinence, Urge
Register for Updates
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction
NCT06061549
Recruiting
The goal of this clinical trial is to test an experimental gene therapy in participants with heart failure with preserved ejection fraction, also known as diastolic heart failure. The main questions it aims to answer are: * safety and tolerability of the gene therapy; and * whether the gene therapy helps the heart ventricles relax during filling. Participants will undergo a one-time infusion of the gene therapy in the cardiac catheterization laboratory and then be followed for safety and effect... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
09/23/2023
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Register for Updates
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
NCT03037164
Recruiting
Stage A: To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC transfusion support. Stage B: To provide early access to the INTERCEPT pathogen reduction system for RBC in regions where a substantial proportion of the population has been infected or is at risk of a transfusion-transmissible infection. The objectives and design of... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
09/11/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Anemia
Register for Updates
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
NCT04054310
Recruiting
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/07/2023
Locations: Liver Center of Texas, Dallas, Texas
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
CLUE: CLinical Utility Study of EsoGuard
NCT06030180
Recruiting
Utilize real-world data from the commercial use of EsoGuard testing on samples collected with EsoCheck (EC/EG) to evaluate the impact of EsoGuard results on health care provider's decision for endoscopy referral. Assess patient compliance with recommendations for upper endoscopy, and relationship of compliance to positive EsoGuard results.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
09/06/2023
Locations: James E Race, Dallas, Texas
Conditions: Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophagus Adenocarcinoma
Register for Updates